Table 2.
Main targets of the YGJD in the treatment of CHB-related liver fibrosis.
| Symbol | Entrez ID | Protein name | BC (10−3) |
|---|---|---|---|
| RELA | 5970 | Transcription factor p65, NF-κB subunit | 5.28 |
| EGFR | 1956 | Epidermal growth factor receptor | 2.66 |
| RAC3 | 5881 | Ras-related C3 botulinum toxin substrate 3 | 1.44 |
| FOS | 2353 | Proto-oncogene c-Fos, AP-1 transcription factor subunit | 1.25 |
| IFNA1 | 3439 | Interferon-alpha 1/13 | 1.05 |
| JUN | 3725 | Transcription factor AP-1 | 0.89 |
| MAPK12 | 6300 | Mitogen-activated protein kinase 12 | 0.61 |
| FN1 | 2335 | Fibronectin | 0.59 |
| INPP5B | 3633 | Type II inositol 1,4,5-trisphosphate 5-phosphatase | 0.56 |
| TGFB3 | 7043 | Transforming growth factor-beta 3 | 0.47 |
| RXRG | 6258 | Retinoic acid receptor RXR-gamma | 0.45 |
| CYP2C9 | 1559 | Cytochrome P450 2C9 | 0.43 |
| OCRL | 4952 | Inositol polyphosphate 5-phosphatase OCRL-1 | 0.36 |
| IL1B | 3553 | Interleukin-1-beta | 0.35 |
| HGS | 9146 | Hepatocyte growth factor-regulated tyrosine kinase substrate | 0.32 |